Cerebrospinal fluid biomarkers in neurodegenerative disorders

IF 0.5 Q4 CLINICAL NEUROLOGY

Future Neurology Pub Date : 2019-02-01 DOI:10.2217/FNL-2018-0029

Thalia T Robey, P. Panegyres

引用次数: 23

Abstract

Neurodegenerative diseases represent a daunting challenge in clinical diagnosis and management. Biomarkers that might aid in the diagnosis of these devastating and globally important diseases are urgently sought and required. Here we describe the application and state of development of a range of cerebrospinal fluid biomarkers in common neurodegenerative disorders including Alzheimer's disease, frontotemporal dementia and prion diseases.

查看原文本刊更多论文

神经退行性疾病的脑脊液生物标志物

神经退行性疾病在临床诊断和管理方面是一项艰巨的挑战。迫切需要有助于诊断这些具有毁灭性和全球重要性的疾病的生物标志物。在这里，我们描述了一系列脑脊液生物标志物在常见神经退行性疾病中的应用和发展状况，包括阿尔茨海默病、额颞叶痴呆和朊病毒疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Neurology CLINICAL NEUROLOGY-

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.